What We Do
eFund was founded with the goal to achieve consistently higher returns and more exits from angel investments. By investing in promising BC startups that solve global problems you support the local knowledge economy and access returns from global markets.
By investing via teams, we are able to do better due diligence, by leveraging the domain expertise of our investors and by providing post investment advice and connections to the companies we invested in.
Join our team of 100+ angel investors and enjoy the rewards of angel investing.
Diversify your portfolio and invest in local entrepreneurs.
Looking for the right angel investor? Here is what we’re looking for.
Want to Learn More About Angel Investing with eFund?
- eFund invested in more than 25 BC Startups. Take a look at our current portfolio
- See vetted BC Startups pitch and meet active eFund investors at an eFund Event, Angel Investor Meeting at VANTEC or Angel Forum
- Meet with an E-Fund Investment Team Member and get complimentary copy of “A Practical Guide to Angel Investing“
- Sign up below for our eFund Angel Investing Newsletter and get notified for upcoming workshops and events.
Learn how we operate and participate in deal screening and due diligence. Private meeting of eFund angel investors and their invited guests.
Our Investment Activity Since 2011
Follow Up Meetings
Due Diligence Reports
Exits to Date
Our Portfolio Companies
Mazza Innovation has commercialized the world’s first phytochemical extraction technology, producing high value extracts from plants, using sustainable, high performance and cost effective science.
Views IQ is a medical imaging company focusing on biological microscopic applications of pathology slides. This challenging arena is the last frontier in medical digitizing technologies.
Aspect Biosystems is a biotechnology company specializing in 3D bioprinting and tissue engineering.
Microdermics is a Vancouver-based company focused on commercializing a novel hollow microneedle delivery platform targeting the multi-billion biopharmaceutical market, disrupting the traditional use of hypodermic-based drug injections. E-Fund invested in February 2017. E-Fund II and III